Keenan A. Walker

Dr. Keenan A. Walker

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in JAMA
Verified
Journal Article
Open access
PDF file
KWKeenan A. Walker
Keenan A. Walker
ASA. Richey Sharrett
A. Richey Sharrett
AWAozhou Wu
Aozhou Wu
ASAndrea L. C. Schneider
Andrea L. C. Schneider
MAMarilyn Albert
Marilyn Albert
RGRebecca F. Gottesman
Rebecca F. Gottesman
High blood pressure, and in certain circumstances, low blood pressure, have been associated with cognitive decline and dementia in community-based studies, suggesting that blood pressure may serve as a viable target for primary or secondary dementia prevention.1 Accumulating evidence2,3 suggests that hypertension during midlife may be a risk factor for cognitive decline and dementia. While the relationship of elevated blood pressure during the 7th, 8th, and 9th decades of life with cognitive outcomes is less clear,1 several studies indicate that optimal blood pressure ranges for older adults may depend on earlier blood pressure characteristics.4,5 However, few large-scale studies have examined dynamic midlife to late-life blood pressure patterns longitudinally in relation to subsequent cognitive decline and dementia, making it difficult to draw firm conclusions.4,6

12 March 2019 in Neurology
Verified
Journal Article
Closed access
KWKeenan A. Walker
Keenan A. Walker
RGRebecca F. Gottesman
Rebecca F. Gottesman
AWAozhou Wu
Aozhou Wu
DKDavid S. Knopman
David S. Knopman
AGAlden L. Gross
Alden L. Gross
BWB. Gwen Windham
B. Gwen Windham
To examine the association between systemic inflammation measured during midlife and 20-year cognitive decline. Within the Atherosclerosis Risk in Communities cohort study, inflammatory biomarkers were measured during middle adulthood. We created an inflammation composite score using 4 blood biomarkers measured at visit 1 (fibrinogen, white blood cell count, von Willebrand factor, and factor VIII); we measured C-reactive protein (CRP) at visit 2. Cognition was assessed over 3 visits spanning 20 years using measures of memory, executive function, and language. A total of 12,336 participants (baseline age 56.8 [5.7], 21% black, 56% women) were included. After adjusting for demographic variables, vascular risk factors, and comorbidities, each standard deviation (SD) increase in midlife inflammation composite score was associated with an additional 20-year decline of -0.035 SD (95% confidence interval: -0.062 to -0.007) on the cognitive composite score. We found a similar association between each SD increase in midlife CRP level and additional 20-year cognitive decline (-0.038 SD, 95% confidence interval: -0.057 to -0.019). Participants with a midlife inflammation composite score in the top quartile had a 7.8% steeper cognitive decline, compared to participants in the lowest quartile; CRP in the top quartile was associated with an 11.6% steeper cognitive decline. In cognitive domain-specific analyses, elevated midlife inflammatory markers were most consistently associated with declines in memory. Results were similar after adjusting for attrition using inverse probability weighting. Our findings highlight what may be an early pathogenic role for systemic inflammation as a driver of cognitive decline in the decades leading up to older adulthood.

14 May 2021 in Nature Aging
Verified
Journal Article
Closed access
PDF file
KWKeenan A. Walker
Keenan A. Walker
JCJingsha Chen
Jingsha Chen
JZJingning Zhang
Jingning Zhang
MFMyriam Fornage
Myriam Fornage
YYYunju Yang
Yunju Yang
JCJosef Coresh
Josef Coresh

2 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
JLJack C. Lennon
Jack C. Lennon
SAStephen L. Aita
Stephen L. Aita
VBVictor A. Del Bene
Victor A. Del Bene
TRTasha Rhoads
Tasha Rhoads
ZRZachary J. Resch
Zachary J. Resch
KWKeenan A. Walker
Keenan A. Walker

15 July 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KWKeenan A. Walker
Keenan A. Walker
NBNathan Basisty
Nathan Basisty
David WilsonDavid Wilson
David Wilson
LFLuigi Ferrucci
Luigi Ferrucci
Aging is characterized by the accumulation of damage to macromolecules and cell architecture that triggers a proinflammatory state in blood and solid tissues, termed inflammaging. Inflammaging has been implicated in the pathogenesis of many age-associated chronic diseases as well as loss of physical and cognitive function. The search for mechanisms that underlie inflammaging focused initially on the hallmarks of aging, but it is rapidly expanding in multiple directions. Here, we discuss the threads connecting cellular senescence and mitochondrial dysfunction to impaired mitophagy and DNA damage, which may act as a hub for inflammaging. We explore the emerging multi-omics efforts that aspire to define the complexity of inflammaging — and identify molecular signatures and novel targets for interventions aimed at counteracting excessive inflammation and its deleterious consequences while preserving the physiological immune response. Finally, we review the emerging evidence that inflammation is involved in brain aging and neurodegenerative diseases. Our goal is to broaden the research agenda for inflammaging with an eye on new therapeutic opportunities.

13 January 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MFMichael Fang
Michael Fang
JHJiaqi Hu
Jiaqi Hu
JWJordan Weiss
Jordan Weiss
DKDavid S. Knopman
David S. Knopman
MAMarilyn Albert
Marilyn Albert
JCJosef Coresh
Josef Coresh